H
Heike I. Grabsch
Researcher at University of Leeds
Publications - 188
Citations - 6791
Heike I. Grabsch is an academic researcher from University of Leeds. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 36, co-authored 149 publications receiving 4643 citations. Previous affiliations of Heike I. Grabsch include St James's University Hospital & Maastricht University Medical Centre.
Papers
More filters
Journal ArticleDOI
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer.
Jakob Nikolas Kather,Alexander T. Pearson,Niels Halama,Dirk Jäger,Jeremias Krause,Sven H. Loosen,Alexander Marx,Peter Boor,Frank Tacke,Ulf P. Neumann,Heike I. Grabsch,Heike I. Grabsch,Takaki Yoshikawa,Hermann Brenner,Jenny Chang-Claude,Jenny Chang-Claude,Michael Hoffmeister,Christian Trautwein,Tom Luedde +18 more
TL;DR: It is shown that deep residual learning can predict MSI directly from H&E histology, which is ubiquitously available and has the potential to provide immunotherapy to a much broader subset of patients with gastrointestinal cancer.
Journal ArticleDOI
Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process
Cathy Bennett,Nimish Vakil,Jacques J. Bergman,Rebecca Harrison,Robert D. Odze,Michael Vieth,Scott Sanders,Oliver Pech,Gaius Longcroft-Wheaton,Yvonne Romero,John M. Inadomi,Jan Tack,Douglas A. Corley,Hendrik Manner,Susi Green,David Al Dulaimi,Haythem Ali,Bill Allum,Mark R Anderson,Howard Curtis,Gary W. Falk,M. Brian Fennerty,Grant Fullarton,Kausilia K. Krishnadath,Stephen J. Meltzer,David Armstrong,Robert A. Ganz,Gianpaolo Cengia,James J. Going,John R. Goldblum,Charles Gordon,Heike I. Grabsch,Chris Haigh,Michio Hongo,David Johnston,Ricky Forbes-Young,Elaine Kay,Philip Kaye,Toni Lerut,Laurence Lovat,Lars Lundell,Philip Mairs,Tadakuza Shimoda,Stuart J. Spechler,Stephen J. Sontag,Peter Malfertheiner,Iain A. Murray,Manoj Nanji,David N. Poller,Krish Ragunath,Jaroslaw Regula,Renzo Cestari,Neil A. Shepherd,Rajvinder Singh,Hubert J. Stein,Nicholas J. Talley,Jean Paul Galmiche,Tony C.K. Tham,Peter Watson,Lisa Yerian,Massimo Rugge,Thomas W. Rice,John Hart,Stuart Gittens,David Hewin,Juergen Hochberger,Peter J. Kahrilas,Sean L. Preston,Richard E. Sampliner,Prateek Sharma,Robert C. Stuart,Kenneth K. Wang,Irving Waxman,Chris Abley,Duncan Loft,Ian D. Penman,Nicholas J. Shaheen,Amitabh Chak,Gareth Davies,L. J. Dunn,Yngve Falck-Ytter,John deCaestecker,Pradeep Bhandari,Christian Ell,S. Michael Griffin,Stephen Attwood,Hugh Barr,John J.B. Allen,Mark K. Ferguson,Paul Moayyedi,Janusz Jankowski,Janusz Jankowski,Janusz Jankowski +92 more
TL;DR: An international, multidisciplinary, systematic, evidence-based review of different management strategies for patients with Barrett's esophagus and dysplasia or early-stage EA and developed a data-sifting platform and used the Delphi process to create evidence- based consensus statements.
Journal ArticleDOI
Pan-cancer image-based detection of clinically actionable genetic alterations
Jakob Nikolas Kather,Jakob Nikolas Kather,Lara R. Heij,Lara R. Heij,Heike I. Grabsch,Heike I. Grabsch,Chiara Loeffler,Amelie Echle,Hannah Sophie Muti,Jeremias Krause,Jan M. Niehues,Kai A. J. Sommer,Peter Bankhead,Loes F. S. Kooreman,Jefree J. Schulte,Nicole A. Cipriani,Roman D. Buelow,Peter Boor,Nadina Ortiz-Brüchle,Andrew M. Hanby,Valerie Speirs,Sara Kochanny,Akash Patnaik,Andrew Srisuwananukorn,Hermann Brenner,Michael Hoffmeister,Piet A. van den Brandt,Dirk Jäger,Christian Trautwein,Alexander T. Pearson,Tom Luedde +30 more
TL;DR: The findings show that a single deep learning algorithm can be trained to predict a wide range of molecular alterations from routine, paraffin-embedded histology slides stained with hematoxylin and eosin.
Journal ArticleDOI
HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.
TL;DR: This is the largest study to date demonstrating in two independent series that HER2 expression is not related to gastric cancer patient prognosis and that only a very small subgroup of intestinal type GC may potentially respond to HER2 targeting therapy.
Journal ArticleDOI
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
Filippo Pietrantonio,Rosalba Miceli,Alessandra Raimondi,Young-Woo Kim,Won Ki Kang,Ruth E Langley,Yoon Young Choi,Kyoung-Mee Kim,Matthew Nankivell,Federica Morano,Andrew Wotherspoon,Nicola Valeri,Nicola Valeri,Myeong Cherl Kook,Ji Yeong An,Heike I. Grabsch,Heike I. Grabsch,Giovanni Fucà,Sung Hoon Noh,Tae Sung Sohn,Sung Kim,Maria Di Bartolomeo,David Cunningham,Jeeyun Lee,Jae Ho Cheong,Elizabeth C Smyth +25 more
TL;DR: In patients with resectable primary GC, MSI is a robust prognostic marker that should be adopted as a stratification factor by clinical trials and Chemotherapy omission and/or immune checkpoint blockade should be investigated prospectively in MSI-high GCs according to clinically and pathologically defined risk of relapse.